Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
Public ClinicalTrials.gov record NCT02015663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Study identification
- NCT ID
- NCT02015663
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Interventions
- Tobramycin Inhalation Powder Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2013
- Primary completion
- Nov 30, 2014
- Completion
- Nov 30, 2014
- Last update posted
- Mar 28, 2017
2014
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Mobile | Alabama | 36608-1128 | — |
| Novartis Investigative Site | Los Angeles | California | 90027 | — |
| Novartis Investigative Site | Sacramento | California | 95819 | — |
| Novartis Investigative Site | Ventura | California | 93003 | — |
| Novartis Investigative Site | Altamonte Springs | Florida | 32701 | — |
| Novartis Investigative Site | Jacksonville | Florida | 32207 | — |
| Novartis Investigative Site | Miami | Florida | 33136 | — |
| Novartis Investigative Site | Orlando | Florida | 32806 | — |
| Novartis Investigative Site | Pensacola | Florida | 32504 | — |
| Novartis Investigative Site | Glenview | Illinois | 60025 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46202 | — |
| Novartis Investigative Site | Iowa City | Iowa | 52242 | — |
| Novartis Investigative Site | St Louis | Missouri | 63104 | — |
| Novartis Investigative Site | New Hyde Park | New York | 11040 | — |
| Novartis Investigative Site | New York | New York | 10595 | — |
| Novartis Investigative Site | Akron | Ohio | 44308 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73112 | — |
| Novartis Investigative Site | Portland | Oregon | 92772 | — |
| Novartis Investigative Site | Hershey | Pennsylvania | 17033-8050 | — |
| Novartis Investigative Site | Austin | Texas | 78723 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02015663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02015663 live on ClinicalTrials.gov.